Brexanolone - Lipocine
Alternative Names: BRLIZIO; LPCN-1154; LPCN-1154A; LPCN-2201Latest Information Update: 11 Aug 2026
At a glance
- Originator Lipocine
- Class Antidepressants; Antiepileptic drugs; Ear disorder therapies; Small molecules; Steroids
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Postnatal depression
Highest Development Phases
- Phase III Postnatal depression
- Phase I Major depressive disorder
Most Recent Events
- 04 Aug 2026 Lipocine schedules a guidance meeting with the FDA in the third quarter of 2026
- 02 Apr 2026 Final efficacy data from a phase III trial in Postnatal depression released by Lipocine
- 10 Mar 2026 Lipocine plans to file a 505(b) New Drug Application (NDA) for Postnatal depression in mid of 06. (946151)